Keywords: roche, t-20, found, well-tolerated, conjuction, partner, trimeris
Roche's T-20 found to be well-tolerated
Article | 19 December 2001
Roche, in conjuction with partner Trimeris of North Carolina, USA, hasprovided an early indication that its fusion inhibitor pentafuside, T-20, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
